Growth Owing to Increasing Prevalence of Respiratory Diseases

Dry powder inhalers are devices that deliver medication to the lungs in a powder form. They are used for treating conditions like asthma and chronic obstructive pulmonary disease. Some of the main advantages of dry powder inhalers include ease of use, precise dosing, and enhanced stability of medication in dry powder form over liquids.

RF Power Semiconductor Market Size of respiratory diseases along with rising geriatric population and increasing pollution levels globally have resulted in a significant increase in demand for respiratory drugs and devices like dry powder inhalers.

The global pharmaceutical dry powder inhaler market size was valued at US$ 10.2 billion in 2022 and is estimated to be valued at US$ 15.8 billion in 2028 exhibiting a CAGR of 6.5% over the forecast period 2022-2028.

Key Takeaways

Key players operating in the pharmaceutical dry powder inhaler market are GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A, Cipla Inc., 3M, Novartis AG. Key players are focusing on new product launches and geographical expansion to strengthen their market position. For instance, in 2022, GSK launched an easy-to-use dry powder inhaler Ellipta for COPD and asthma patients in China.

The market offers significant growth opportunities owing to the increasing RF Power Semiconductor Market Companies Additionally, rising adoption of effective pulmonary drug delivery routes especially for biologics and large molecule drugs is expected to augment the demand of dry powder inhalers over the forecast period.

Get More Insights On, Rf Power Semiconductor Market